Alcobra Ltd (ADHD.OQ)

ADHD.OQ on NASDAQ Stock Exchange Global Market

2 Oct 2015
Change (% chg)

$-0.03 (-0.52%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for ADHD.OQ


Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and... (more)


Beta: --
Market Cap(Mil.): $121.98
Shares Outstanding(Mil.): 21.18
Dividend: --
Yield (%): --


  ADHD.OQ Industry Sector
P/E (TTM): -- 58.81 32.90
EPS (TTM): -1.75 -- --
ROI: -74.38 2.96 14.19
ROE: -74.38 4.73 15.12
Search Stocks

Alcobra's only drug fails mid-stage trial for genetic disorder

- The only drug in Alcobra Ltd's pipeline failed a mid-stage trial testing it against a type of genetic disorder that can cause autism and ADHD, sending the company's shares down as much as 19 percent on Wednesday.

24 Jun 2015

UPDATE 2-Alcobra's only drug fails mid-stage trial for genetic disorder

* Piper Jaffray analyst says selloff an "oversold opportunity" (Adds background, analyst comments, updates shares)

24 Jun 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : ValuEngine, Inc.
Provider : Reuters Investment Profile
Provider : ValuEngine, Inc.
Provider : Thomson Reuters StreetEvents
Provider : ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks